Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 244

1.

Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use - Advisory Committee on Immunization Practices (ACIP), 2010.

Centers for Disease Control and Prevention (CDC)..

MMWR Morb Mortal Wkly Rep. 2010 Mar 12;59(9):273.

3.

Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, Baker CJ, Messonnier NE; Centers for Disease Control and Prevention (CDC)..

MMWR Recomm Rep. 2013 Mar 22;62(RR-2):1-28.

4.

Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents.

Jackson LA, Baxter R, Reisinger K, Karsten A, Shah J, Bedell L, Dull PM; V59P13 Study Group..

Clin Infect Dis. 2009 Jul 1;49(1):e1-10. doi: 10.1086/599117.

PMID:
19476428
5.

Updated recommendations for use of meningococcal conjugate vaccines --- Advisory Committee on Immunization Practices (ACIP), 2010.

Centers for Disease Control and Prevention (CDC)..

MMWR Morb Mortal Wkly Rep. 2011 Jan 28;60(3):72-6.

6.

Use of MenACWY-CRM vaccine in children aged 2 through 23 months at increased risk for meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2013.

MacNeil JR, Rubin L, McNamara L, Briere EC, Clark TA, Cohn AC; Meningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, CDC..

MMWR Morb Mortal Wkly Rep. 2014 Jun 20;63(24):527-30.

7.

Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.

Perrett KP, Snape MD, Ford KJ, John TM, Yu LM, Langley JM, McNeil S, Dull PM, Ceddia F, Anemona A, Halperin SA, Dobson S, Pollard AJ.

Pediatr Infect Dis J. 2009 Mar;28(3):186-93. doi: 10.1097/INF.0b013e31818e037d.

PMID:
19209097
8.

Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers.

Halperin SA, Diaz-Mitoma F, Dull P, Anemona A, Ceddia F.

Eur J Clin Microbiol Infect Dis. 2010 Mar;29(3):259-67. doi: 10.1007/s10096-009-0848-8. Epub 2009 Dec 22.

PMID:
20033465
9.

Infant meningococcal vaccination: Advisory Committee on Immunization Practices (ACIP) recommendations and rationale.

Centers for Disease Control and Prevention (CDC)..

MMWR Morb Mortal Wkly Rep. 2013 Jan 25;62(3):52-4.

11.

Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants.

Klein NP, Reisinger KS, Johnston W, Odrljin T, Gill CJ, Bedell L, Dull P.

Pediatr Infect Dis J. 2012 Jan;31(1):64-71. doi: 10.1097/INF.0b013e31823dce5c. Erratum in: Pediatr Infect Dis J. 2012 Oct;31(10):1105.

PMID:
22094635
13.

Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine.

Macneil JR, Cohn AC, Zell ER, Schmink S, Miller E, Clark T, Messonnier NE; Active Bacterial Core surveillance (ABCs) Team and MeningNet Surveillance Partners..

Pediatr Infect Dis J. 2011 Jun;30(6):451-5. doi: 10.1097/INF.0b013e31820a8b3c.

PMID:
21206392
14.

Safety and immunogenicity of an investigational meningococcal ACWY conjugate vaccine (MenACWY-CRM) in healthy Indian subjects aged 2 to 75 years.

Lalwani S, Agarkhedkar S, Gogtay N, Palkar S, Agarkhedkar S, Thatte U, Vakil H, Jonnalagedda R, Pedotti P, Hoyle M, Bhusal C, Arora A.

Int J Infect Dis. 2015 Sep;38:36-42. doi: 10.1016/j.ijid.2015.07.003. Epub 2015 Jul 9.

15.

Recommendations for Use of Meningococcal Conjugate Vaccines in HIV-Infected Persons - Advisory Committee on Immunization Practices, 2016.

MacNeil JR, Rubin LG, Patton M, Ortega-Sanchez IR, Martin SW.

MMWR Morb Mortal Wkly Rep. 2016 Nov 4;65(43):1189-1194. doi: 10.15585/mmwr.mm6543a3.

16.

Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents.

Baxter R, Reisinger K, Block SL, Izu A, Odrljin T, Dull P.

J Pediatr. 2014 Jun;164(6):1409-15.e4. doi: 10.1016/j.jpeds.2014.02.025. Epub 2014 Mar 20.

PMID:
24657122
17.

Report from the Advisory Committee on Immunization Practices (ACIP): decision not to recommend routine vaccination of all children aged 2-10 years with quadrivalent meningococcal conjugate vaccine (MCV4).

Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC)..

MMWR Morb Mortal Wkly Rep. 2008 May 2;57(17):462-5.

18.

Safety and immunogenicity of an investigational quadrivalent meningococcal CRM(197) conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America.

Stamboulian D, Lopardo G, Lopez P, Cortes-Barbosa C, Valencia A, Bedell L, Karsten A, Dull PM.

Int J Infect Dis. 2010 Oct;14(10):e868-75. doi: 10.1016/j.ijid.2010.03.017. Epub 2010 Jul 22.

19.

Menveo®): a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y.

Cooper B, DeTora L, Stoddard J.

Expert Rev Vaccines. 2011 Jan;10(1):21-33. doi: 10.1586/erv.10.147. Review.

PMID:
21162617
20.

Use of Serogroup B Meningococcal Vaccines in Persons Aged ≥10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015.

Folaranmi T, Rubin L, Martin SW, Patel M, MacNeil JR; Centers for Disease Control (CDC)..

MMWR Morb Mortal Wkly Rep. 2015 Jun 12;64(22):608-12. Erratum in: MMWR Morb Mortal Wkly Rep. 2015 Jul 31;64(29):806.

Supplemental Content

Support Center